Candidate genes tested for correlation with response
| Parameter . | No. of patients . | No. of responses (%) . | Univariate . | Multivariate . | Odds ratio . | Score . |
|---|---|---|---|---|---|---|
| BAD, median | ||||||
| Less than 4.4 | 19 | 7 (37) | .638 | — | — | — |
| 4.4 or greater | 18 | 8 (44) | ||||
| BAX, median | ||||||
| Less than 10.4 | 19 | 5 (26) | .0703-151 | .017 | 26.1 | 1 |
| 10.4 or greater | 18 | 10 (56) | 1.0 | 0 | ||
| BCL-2, median | ||||||
| Less than 4.2 | 19 | 8 (42) | .842 | — | — | — |
| 4.2 or greater | 18 | 7 (39) | ||||
| BCL-XL, median | ||||||
| Less than 10.7 | 18 | 6 (33) | .310 | — | — | — |
| 10.7 or greater | 18 | 9 (50) | ||||
| MDR-1, median | ||||||
| Less than 3.8 | 19 | 9 (47) | .385 | — | — | — |
| 3.8 or greater | 18 | 6 (33) | ||||
| MDM-2, median | ||||||
| Less than 1.8 | 18 | 9 (50) | .310 | — | — | — |
| 1.8 or greater | 18 | 6 (33) | ||||
| MRP, median | ||||||
| Less than 24.0 | 16 | 10 (63) | .0183-151 | .011 | 1.0 | 0 |
| 24.0 or greater | 21 | 5 (24) | 14.4 | 1 | ||
| Survivin, median | ||||||
| Less than 57.6 | 19 | 8 (42) | .842 | — | — | — |
| 57.6 or greater | 18 | 7 (39) | ||||
| BCR-ABL, median | ||||||
| Less than 70 500 | 18 | 9 (50) | .310 | — | — | — |
| 70 500 or greater | 18 | 6 (33) | ||||
| CFU-GM3-150 day 7, 0.1 μM imatinib | ||||||
| 50% or greater | 26 | 12 (46) | .149 | — | — | — |
| Less than 50% | 10 | 2 (20) |
| Parameter . | No. of patients . | No. of responses (%) . | Univariate . | Multivariate . | Odds ratio . | Score . |
|---|---|---|---|---|---|---|
| BAD, median | ||||||
| Less than 4.4 | 19 | 7 (37) | .638 | — | — | — |
| 4.4 or greater | 18 | 8 (44) | ||||
| BAX, median | ||||||
| Less than 10.4 | 19 | 5 (26) | .0703-151 | .017 | 26.1 | 1 |
| 10.4 or greater | 18 | 10 (56) | 1.0 | 0 | ||
| BCL-2, median | ||||||
| Less than 4.2 | 19 | 8 (42) | .842 | — | — | — |
| 4.2 or greater | 18 | 7 (39) | ||||
| BCL-XL, median | ||||||
| Less than 10.7 | 18 | 6 (33) | .310 | — | — | — |
| 10.7 or greater | 18 | 9 (50) | ||||
| MDR-1, median | ||||||
| Less than 3.8 | 19 | 9 (47) | .385 | — | — | — |
| 3.8 or greater | 18 | 6 (33) | ||||
| MDM-2, median | ||||||
| Less than 1.8 | 18 | 9 (50) | .310 | — | — | — |
| 1.8 or greater | 18 | 6 (33) | ||||
| MRP, median | ||||||
| Less than 24.0 | 16 | 10 (63) | .0183-151 | .011 | 1.0 | 0 |
| 24.0 or greater | 21 | 5 (24) | 14.4 | 1 | ||
| Survivin, median | ||||||
| Less than 57.6 | 19 | 8 (42) | .842 | — | — | — |
| 57.6 or greater | 18 | 7 (39) | ||||
| BCR-ABL, median | ||||||
| Less than 70 500 | 18 | 9 (50) | .310 | — | — | — |
| 70 500 or greater | 18 | 6 (33) | ||||
| CFU-GM3-150 day 7, 0.1 μM imatinib | ||||||
| 50% or greater | 26 | 12 (46) | .149 | — | — | — |
| Less than 50% | 10 | 2 (20) |
— indicates parameters that were not significant in univariate analysis.
Colony survival in percent of control; all other dose/time points were also tested, but also failed to show a correlation with response.
Parameters that were significant at P < .1 in univariate analysis were included in the multivariate model.